Current Strategies, Diagnostic Approaches, and Advanced Therapeutics for the Treatment of Patients with Interstitial Lung Disease

Current Strategies, Diagnostic Approaches, and Advanced Therapeutics for the Treatment of Patients with Interstitial Lung Disease

CME/CE Symposium at the Congress of Clinical Rheumatology East Meeting

Date/Time

Friday, August 13th, 2021
3:55 pm – 4:55 pm Central Time

Location

Hilton Sandestin Beach Golf Resort & Spa
Emerald Ballroom [Main Session Room]
4000 Sandestin Blvd South
Miramar Beach, FL 32550
Registration Below

Date/Time

Friday, August 13th, 2021
3:55 pm – 4:55 pm Central Time 

Location

Hilton Sandestin Beach Golf Resort & Spa
Emerald Ballroom [Main Session Room]
4000 Sandestin Blvd South
Miramar Beach, FL 32550

Target Audience

Rheumatologists, primary care physicians, physician assistants, nurse practitioners, nurses, hospital and community pharmacists, and other healthcare professionals involved in the treatment and management of patients with rheumatological disorders

Program Overview 

This interactive CME/CE program will highlight recent advances in the treatment and management of patients with interstitial lung disease (ILD). The expert faculty, Drs. Dinesh Khanna and Kevin Flaherty, will first review best practices for screening and diagnosing patients. Following, recent clinical trial data of both emerging and approved agents will be analyzed and clinical relevance debated from the perspective of both a rheumatologist and a pulmonologist. To conclude, the faculty will relay strategies for engaging the interprofessional team to improve outcomes and quality of life for patients with interstitial lung disease. 

Agenda

I. Screening and Diagnosis of SSc-ILD

II. Clinical Trial Review: FDA Approved and Emerging Treatment Options for ILD, Including (nRTK) and (RTK) Inhibitors

III. What Does RTK Stand For?

IV. Engaging the Interprofessional Team to Build Positive Outcomes for Patients with ILD

V. Interactive Expert Panel Discussion 

Educational Objectives 

  1. Understand diagnostic methods and clinical presentations of ILD, as well as methods used to monitor lung function
  2. Review recent clinical trial data on therapeutic agents used to slow the rate of lung function decline, including nRTK and RTK inhibitors
  3. Engage in shared decision-making and communication with the interprofessional team while developing treatment plans for patients with ILD

Faculty

Dinesh Khanna, MD, MSc
Scleroderma Program
University of Michigan School of Medicine
Ann Arbor, Michigan

Kevin Robert Flaherty, MD
Professor of Internal Medicine
Michigan Medicine Pulmonary Clinic, Taubman Center
University of Michigan
Ann Arbor, Michigan

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit ™

AcademicCME designates this live material for a maximum of 1.0 CNE Contact Hour (Provider #P0491). 

Participants should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs 

For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300. 

Financial Support

This activity has been supported by an independent educational grant from Boehringer Ingelheim

 

Provided by AcademicCME 

AcademicLogo

*Further details regarding how to tune in to this live symposium will be emailed to the address used to register prior to the event.